MacroGenics appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

MACROGENICS INC

Appointments effective January 3, 2023; Liu joins Science & Tech Committee, Karson joins Audit Committee.
Board expands to ten directors, nine of whom are independent.
Dr. Liu is a gene therapy, vaccines, and immunotherapy expert; former exec at Merck and Chiron.
Meenu Chhabra Karson is a biopharma executive; previously CEO of Proteostasis Therapeutics and led its IPO.
Karson received an option to purchase 36,000 shares vesting monthly over 36 months.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Meenu Chhabra Karson

Director

MGNX · MACROGENICS INC

Effective: 2023-01-03
Filed: January 5, 2023, 6:59 PM ET

On January 3, 2023, the Board of Directors (the "Board") of MacroGenics, Inc. (the "Company") approved the appointment of Meenu Chhabra Karson to serve as a director on the Board, effective January 3, 2023 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Meenu Chhabra Karson was appointed as Director at MACROGENICS INC.

Action: appointed
Role: Director

Exact text from the filing

On January 3, 2023, the Board of Directors (the "Board") of MacroGenics, Inc. (the "Company") approved the appointment of Meenu Chhabra Karson to serve as a director on the Board, effective January 3, 2023 (the “Effective Date”).

View on SEC.gov

MACROGENICS INC filing history →

Source: SEC EDGAR

accession 0001125345-23-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.